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Abstract
CD40 promotes survival, proliferation, and differentiation of
normal B cells but can cause activation-induced cell death in
malignant B lymphocytes. CD40 ligand and anti-CD40 anti-
bodies have been used successfully to induce apoptosis in
lymphoma lines both in vitro and in xenograft tumor models.
Although this makes CD40 an attractive target for antitumor
therapies, the response of malignant B cells to CD40 signaling
is variable, and CD40 stimulation can enhance proliferation
and can increase chemoresistance in some cell lines. It would
therefore be useful to identify markers that predict whether a
specific cell line or tumor will undergo apoptosis when
stimulated with CD40 and to identify targets downstream of
CD40 that affect only the apoptotic arm of CD40 signaling. We
have analyzed gene expression patterns in CD40-sensitive and
CD40-resistant diffuse large B-cell lymphoma (DLBCL) cell
lines to identify signaling pathways that are involved in CD40-
mediated apoptosis. CD40-resistant lines expressed pre-B-cell
markers, including RAG and VPREB, whereas CD40-sensitive
cells resembled mature B cells and expressed higher levels of
transcripts encoding several members of the CD40 signaling
pathway, including LCK and VAV. In addition, CD40-sensitive
DLBCL cell lines also displayed constitutive activation of
extracellular signal-regulated kinase (ERK) and failed to
undergo apoptosis when ERK phosphorylation was inhibited.
In contrast, CD40-resistant lines showed no constitutive
activation of ERK and no increase in ERK activity in response
to CD40 stimulation. Our results suggest that constitutive
activation of ERK may be required for death signaling by
CD40. (Cancer Res 2006; 66(7): 3550-7)
Introduction
CD40 is a member of the tumor necrosis factor receptor
superfamily that is expressed on the surface of B lymphocytes as
well as a variety of nonlymphoid cells (1). Stimulation of CD40 by
CD40L, which is expressed primarily on T cells, is essential for
normal B lymphocyte development and function (1). The
importance of CD40 in maintaining normal immune function is
evident in individuals with inactivating mutations in CD40 or
CD40L who suffer from severe immunodeficiency characterized by
susceptibility to bacterial infections and accumulation of IgM+
B cells that are unable to switch their immunoglobulin class (1).
CD40 is first expressed before the rearrangement of immuno-
globulin heavy chain genes in early B-cell development; its
expression is maintained through all subsequent stages of B-cell
development and is not lost during malignant transformation (2).
Malignant B lymphocytes and other CD40-positive tumor cells
differ from normal B cells in that they undergo apoptosis following
CD40 stimulation (3). CD40 stimulation shows promise as an
antitumor therapy in murine models of B-cell lymphoma and
breast cancer (4, 5). CD40 ligand has also been tested in phase I
clinical trials (6); however, the use of CD40-directed therapy
remains controversial because CD40 signaling can enhance cell
proliferation and survival as well as induce resistance to
chemotherapeutic agents in some B-cell malignancies (7, 8).
Consequently, elucidation of the mechanisms involved in CD40-
mediated apoptosis may help to identify markers for susceptibility
to CD40-mediated cell death and reveal proteins that specifically
control the apoptotic arm of CD40 signaling.
CD40 stimulation has been shown to activate both the nuclear
factor-nB (NF-nB) and the mitogen-activated protein kinase
(MAPK) signaling pathways (1). NF-nB activation on CD40
stimulation has been extensively studied and is generally
associated with cell survival in both normal and malignant
B lymphocytes (9). In contrast, MAPK activation can have
proliferative or apoptotic effects depending on the stimulus and
cell type. In general, activation of extracellular signal-regulated
kinase (ERK) is associated with survival, whereas activation of
c-Jun NH2-terminal kinase (JNK) and p38 tends to promote apop-
tosis (10). In B lymphocytes, p38 activation has been shown to
promote CD40-induced cell proliferation (11), whereas ERK activa-
tion can be associated with both apoptotic and antiapoptotic
effects (12). The biological effects of CD40 stimulation in B cells are
also strongly dependent on maturation stage, which may reflect
availability of different signal transduction pathways (1).
We hypothesize that cells that differ in their response to CD40
ligation will show differences in gene expression before stimulation,
resulting in the activation of alternate signaling pathways. We
therefore studied expression profiles of CD40-sensitive and CD40-
resistant diffuse large B-cell lymphoma (DLBCL) cell lines and
correlated gene expression profiles of unstimulated cell lines with
their sensitivity to CD40-mediated apoptosis. Resistance to CD40-
mediated cell death was associated with expression of pre-B-cell
markers, whereas susceptibility was correlated with a mature B-cell
phenotype and increased transcript levels for several proteins
involved in CD40 signal transduction. Based on these gene expres-
sion patterns, we investigated the activity of the LCK-VAV-MAPK
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signaling pathway and found that ERK was constitutively activated
in CD40-sensitive cell lines but not CD40-resistant cell lines.
Inhibitor studies indicated that ERK was required to render DLBCL
cell lines susceptible to CD40-mediated cell death.
Materials and Methods
Lymphoma and hybridoma cell lines. DLBCL lines OCI-Ly1, OCI-Ly7,
OCI-Ly8, and Su-DHL4 (13, 14) were provided by Dr. Neil Berinstein
(Ontario Cancer Institute, Toronto, Ontario, Canada). A hybridoma line
producing anti-human CD40 (clone G28.5; ref. 15) was provided by Dr.
Bruce Mazer (McGill University, Montreal, Quebec, Canada). The cell lines
were maintained in RPMI 1640 (Sigma, Oakville, Ontario, Canada)
supplemented with 10% bovine growth serum (VWR Canlab, Montreal,
Quebec, Canada), 0.2 mmol/L glutamine, 0.05 mmol/L h-mercaptoethanol,
100 units/mL penicillin, and 100 Ag/mL streptomycin in a 5% CO2
atmosphere at 37jC. Antibodies against human CD40 (clone G28.5) and
murine IgG (clone HB58) were purified from hybridoma supernatants with a
protein G-Sepharose column as described by the manufacturer (Amersham,
Baie d’Urfe, Quebec, Canada).
CD40 stimulation and assessment of viability. Cells were resuspended
at 1  105/mL in RPMI 1640 supplemented as described above. Anti-CD40
antibody G28.5 and secondary cross-linking antibody HB58 were added to a
final concentration of 10 Ag/mL each, and the cells were incubated at 37jC.
At 24-hour intervals, aliquots of cells were harvested by centrifugation,
washed once in PBS, and resuspended in fluorescence-activated cell sorting
buffer. Nonpermeabilized cells were stained by addition of 1 Ag/mL
propidium iodide, and the density of viable cells was determined using a
FACScan flow cytometer and CellQuest software (Becton Dickinson,
Mississauga, Ontario, Canada) set to count for a fixed 30-second time
interval. To determine the fraction of cells that had undergone apoptosis,
total intracellular DNA content was measured by propidium iodide staining
of ethanol-permeabilized cells as described previously (16). Expression of
CD40 on the cell surface was confirmed by staining nonpermeabilized cells
with a phycoerythrin-linked anti-CD40 antibody (clone 5C3, Becton Dick-
inson) as per manufacturer’s directions and followed by flow cytometry.
Growth inhibition by kinase inhibitors. The Src family kinase inhibitor
PP1 and the MAPK/ERK kinase (MEK) inhibitor U0126 were purchased
from Biomol (Plymouth Meeting, PA) and Cell Signaling Technology
(Beverly, MA), respectively. Kinase inhibition assays were done using cells
seeded at a density of 5  104/mL in 96-well plates, to which kinase
inhibitors were added to final concentrations of 104 to 108 mol/L. The
treated cells were incubated at 37jC for 96 hours, and cell viability was
quantitated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described previously (17). For inhibition of CD40-mediated
apoptosis, the MEK inhibitors U0126 (10 Amol/L) and PD98059 (50 Amol/L)
as well as the p38 inhibitor SB203580 (10 Amol/L; Cell Signaling Technology)
were added 30 minutes before CD40 stimulation. The dose of kinase
inhibitors used in this study has been shown previously to mediate target-
specific effects in lymphocytes (18).
Detection of intracellular phosphorylated ERK by flow cytometry.
Cells were permeabilized in Cytofix/Cytoperm (Becton Dickinson) for 20
minutes and stained with anti-phosphorylated ERK antibody (Cell Signaling
Technology) and FITC-conjugated anti-rabbit secondary antibody (Cedar-
lane Laboratories, Hornby, Ontario, Canada) following the manufacturers’
instructions. The stained cells were analyzed by flow cytometry with a
FACScan flow cytometer and CellQuest software.
Preparation of cell extracts. Nondenatured whole-cell lysates were
prepared by sonicating cells in nondenaturing lysis buffer [20 mmol/L Tris
(pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton
X-100, 1 mmol/L Na3VO4] containing a protease inhibitor cocktail (Roche
Diagnostics, Laval, Quebec, Canada). Cytoplasmic-enriched extracts were
prepared by lysing cells in hypotonic lysis buffer [10 mmol/L HEPES
(pH 7.9), 1.5 mmol/L MgCl2, 100 mmol/L KCl, 1 mmol/L DTT, 1% protease
inhibitor cocktail (Sigma)] followed by shearing through a 23-gauge needle
to release the nuclei. The nuclei were pelleted at 450  g , and the
supernatant (cytoplasmic-enriched cell extract) was removed and stored at
80jC. Protein concentration was determined using the bicinchoninic acid
protein assay (Pierce, Rockford, IL).
Immunoprecipitation and Western blot. LCK was immunoprecipi-
tated from nondenatured cell lysate with a polyclonal rabbit antibody (Cell
Signaling Technology) as recommended by the manufacturer. Proteins were
separated by SDS-PAGE on a 14% acrylamide gel at 180 V for 1 hour and
transferred to a nitrocellulose membrane by electrophoretic transfer at 100
V for 1 hour. Western blots were done as described previously (16). Primary
antibodies against total and phosphorylated ERK, JNK, and p38 (Cell
Signaling Technology) were used at a dilution of 1:100, primary antibodies
against LCK and activated Src family kinases (Cell Signaling Technology)
were diluted 1:500, and peroxidase-conjugated goat anti-mouse or donkey
anti-rabbit secondary antibodies (BioCan Scientific, Mississauga, Ontario,
Canada) were used at a dilution of 1:10,000. The compositions of blocking
and antibody dilution solutions were specified by the manufacturer. Blots
were immersed in Femto West enhanced chemiluminescence staining
solution (Pierce) for 30 seconds and photographed with a Syngene
chemiluminescence imaging system and GeneSnap software. Image size
and contrast were adjusted using Canvas software.
Expression microarrays. Total RNA was prepared from cultured cells
using Trizol reagent according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). The integrity of the purified RNA was verified
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Probes for microarray analysis were prepared using total RNA (10 Ag) and
hybridized to Affymetrix HG-U113A GeneChips (Affymetrix, Santa Clara,
CA) as described previously (19). To minimize technical variability, RNA
processing steps (RNA extraction, probe labeling, and chip hybridization)
were done in parallel for each set of four RNA samples.
The hybridized arrays were scanned, and raw data were extracted using
the Microarray Analysis Suite 5.0 (MAS5; Affymetrix). The raw data were
normalized using RMAExpress (http://stat-www.berkeley.edu/users/
bolstad/RMAExpress/RMAExpress.html; ref. 20) and filtered to exclude
genes that MAS5 did not identify as ‘‘present’’ in any expression profile.
Differentially expressed genes were identified by doing a t test between each
pair of CD40-sensitive and CD40-resistant lines. False-positive error
correction was done to maintain a 10% false discovery rate (21). Genes
whose expression differed significantly and showed the same direction of
change in all four comparisons were considered to be differentially
regulated between sensitive and resistant lines. Functional assessment of
these expression differences was done using contingency table analysis
based on hand-curated lists of NF-nB targets (references obtained from
http://people.bu.edu/gilmore/nf-kb; ref. 22), genes involved in CD40 and
BCR signal transduction (see Supplementary Table S2 for gene lists and
references), B-cell maturation markers (Supplementary Table S2), and the
gene ontology classification of proteins implicated in apoptosis (Affyme-
trix). Figures illustrating relevant expression profiles were prepared using
Genesis (http://genome.tugraz.at/Software/GenesisCenter.html; ref. 23).
Semiquantitative reverse transcription-PCR. RNA isolation and cDNA
synthesis was done as for the microarray analyses. Primers were designed to
span introns to ensure specificity for cDNA as opposed to genomic DNA
sequences. Intron/exon junctions were identified by use of the University of
California at Santa Cruz genome browser (http://www.genome.ucsc.edu;
ref. 24). Primers were designed using Primer3 software (http://frodo.wi.mi-
t.edu/cgi-bin/primer3/primer3_www.cgi; ref. 25), and their specificity was
verified by doing a BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/) of
the National Center for Biotechnology Information ‘‘nr’’ nucleotide
sequence database (26). The following primer pairs were used: BTK , 5V-
TGATGAAGGGCCTCTCTACG and 3V-CGGTGAGAACTCCCAGGTTT; CD9 ,
5V-GACTATGGCTCCGATTCGAC and 3V-AGGAAGCCGAAGAACAGTCC;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5V-GAAGGTGAAGG-
TCGGAGTCA and 3V-GACAAGCTTCCCGTTCTCAG; LCK , 5V-ATGAA-
CTGGTCCGCCATTAC and 3V-CCCGTTGTAGTACCCCATCC; RAG1 , 5V-AG-
AGAGCAGAGAACACACTTTGC and 3V-GATCTCACCCGGAACAGCTT; and
VAV1 , 5V-CACCTGCTGTGAGAAGTTCG and 3V-GTCGGACAGGCCACTGTA-
GAT. PCR amplification was done with 0.01 units/AL Taq DNA polymerase
(Sigma) in PCR buffer (Sigma) containing 2 mmol/L MgCl2, 0.25 Ag/AL
bovine serum albumin (New England Biolabs, Beverly, MA), and 0.1 mmol/L
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each dATP, dCTP, dGTP, and dTTP (Amersham). Amplification was done
with 25 cycles (GAPDH and BTK) or 35 cycles (all other primers) of 30
seconds each at 95jC, 58jC, and 72jC. PCR products were detected by gel
electrophoresis and ethidium bromide staining. Images were acquired with
a Syngene gel documentation system and GeneSnap software. Gene
expression was quantitated with GeneTools software using PCR products
amplified from a cDNA dilution series as a standard curve. Images were
transferred to Canvas software for adjustment of contrast and image size.
Results
Susceptibility of DLBCL cell lines to CD40-mediated cell
death. DLBCL cell lines were screened for susceptibility to CD40-
mediated cell death. The number of viable OCI-Ly7 and Su-DHL4
cells was reduced after 72 hours of exposure to cross-linked anti-
CD40 antibody, whereas the viability of OCI-Ly1 and OCI-Ly8 cells
was unaffected (Fig. 1A). CD40 stimulation also increased the
proportion of cells with sub-G1 DNA content at 48 hours in OCI-Ly7
and Su-DHL4 but not OCI-Ly1 or OCI-Ly8 (Fig. 1B). Expression of
CD40 on the cell surface was confirmed by flow cytometry for all
four cell lines (Fig. 1C).
Gene expression profiling of CD40-sensitive and CD40-
resistant DLBCL lines. To identify preexisting gene expression
patterns that may predict susceptibility to CD40-mediated cell
death, RNA from unstimulated OCI-Ly1, OCI-Ly8, OCI-Ly7, and Su-
DHL4 cells was analyzed on Affymetrix U133A oligonucleotide
arrays. In total, 304 genes were differentially expressed among
CD40-sensitive and CD40-resistant cells (Supplementary Table S1).
Further analysis was restricted to subsets of genes likely to be
involved in CD40 signaling, including regulators of apoptosis,
B-cell-specific genes, and NF-nB-regulated genes. Susceptibility to
CD40-mediated apoptosis was not associated with differences in
expression of proapoptotic or antiapoptotic transcripts, and there
was no statistically significant difference in expression of NF-
nB-regulated genes (Table 1). Differences in expression of
Figure 1. Antiproliferative and apoptotic effects of CD40 signaling differ among DLBCL lines. Cells were seeded at 1  105/mL in supplemented RPMI 1640
containing 10 Ag/mL anti-CD40 and 10 Ag/mL cross-linking secondary antibody (anti-CD40 ) or secondary antibody alone (control ). A, for assessment of cell viability,
aliquots were removed at 24-hour intervals, stained with propidium iodide without prior permeabilization, and analyzed by flow cytometry using a fixed-time setting of
30 seconds to quantitate the number of viable cells per unit volume. Results of two experiments of three replicates each were combined. Bars, SD; where these
are not visible, they are covered by the overlying symbol. Growth of OCI-Ly7 and Su-DHL4 cells was inhibited by cross-linked anti-CD40. For quantitation of apoptosis,
cells were stimulated for 48 hours with anti-CD40 or control antibody as described above and then permeabilized with ethanol before staining with propidium
iodide. Intracellular DNA content was analyzed by flow cytometry. B, cells containing less DNA than the G1 fraction, representing apoptotic cells, were quantitated.
Results from two experiments of three replicates each. Bars, SD. *, P < 0.01, statistically significant differences between control and anti-CD40-treated cells.
The fraction of cells with sub-G1 DNA content increased in OCI-Ly7 and Su-DHL4 cells. C, CD40 could be detected on all four DLBCL cell lines by flow cytometry.
Open histograms, fluorescence from phycoerythrin-conjugated anti-CD40 antibody; shaded histograms, similarly conjugated isotype control antibody. Cells were
not permeabilized before staining, thereby restricting staining to antigens exposed on the cell surface.
Table 1. Differences in gene expression among CD40-





Total unique markers 8,003 NA 298 NA NA
Pre-B-cell markers* 14 0.5 5 38.5 <0.001
Mature, activated B
cell*
18 0.7 3 8.1 <0.005
Pan-B cell* 10 0.4 1 1.1 NS
CD40/BCR signaling* 35 1.3 5 10.5 <0.005
NF-nB regulated* 117 4.4 6 0.6 NS
Apoptosis* 90 3.4 3 0 NS
Antiapoptosis* 56 1.1 0 1.1 NS
Abbreviations: NA, not applicable; NS, not significant.
*Genes in these groups are listed in Supplementary Table S2.
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transcripts encoding B-cell maturation-specific genes and mem-
bers of the CD40 signaling pathway were statistically significant
(Table 1). CD40-resistant OCI-Ly1 and OCI-Ly8 cells expressed
significantly higher levels of pre-B-cell genes, including RAG1,
RAG2, IGLL1, CD9 , and VPREB1 , whereas CD40-sensitive OCI-Ly7
and Su-DHL4 cells expressed higher levels of CD22 and CD38
(Fig. 2). CD40-sensitive cells also expressed higher levels of several
genes in the CD40 signaling pathway, including Bruton’s tyrosine
kinase, VAV, LYN, LCK , and MEK1/MAP2K1 (Fig. 2). Differential
expression of several genes was confirmed by reverse transcrip-
tion-PCR (RT-PCR; Fig. 3). Interestingly, transcripts for two of
these genes could only be detected in one group of cell lines:
RAG1 was easily detectable in CD40-resistant OCI-Ly1 and OCI-
Ly8 cells but absent in CD40-sensitive OCI-Ly7 and Su-DHL4 cells,
and VAV1 was present in CD40-sensitive cells but undetectable in
CD40-resistant cells.
Signaling in the LCK-VAV-MAPK pathway differs in CD40-
sensitive and CD40-resistant cell lines. In lymphoma cells, CD40
signaling is mediated by three interacting pathways. Current
evidence suggests that NF-nB pathway is the most important of
these pathways for controlling cell survival. Surprisingly, our
microarray studies showed that CD40 sensitivity was not
associated with differences in expression of transcripts encoding
members of this pathway but rather with changes in the
expression level of LCK and VAV1, which activate the Ras-
Raf-ERK pathway. To further characterize the association
between the MAPK pathway and CD40 sensitivity, we investigat-
ed activation of LCK (which activates VAV1) and MAPKs (which
are activated by VAV1). LCK is a member of the Src protein
family of kinases, which can be phosphorylated at two sites, one
of which activates the kinase, whereas the other is inhibitory.
Western blots showed that activated LCK was present in all four
Figure 2. Expression profiles of
CD40-sensitive and CD40-resistant DLBCL:
B-cell markers and CD40 signaling.
mRNA from unstimulated DLBCL lines
was analyzed on Affymetrix HG-U113A v 2.0
GeneChips as described in Materials and
Methods. B-cell differentiation markers
and genes in the CD40/BCR signaling
pathway were compared in triplicate samples
of each of the four cell lines. Normalized log2
expression values. Brackets, hierarchical
clustering done with Genesis software (23);
horizontal bar, group of cosegregating
pre-B-cell markers (pre-B ).
CD40-Mediated Death in DLBCL Cell Lines Requires ERK
www.aacrjournals.org 3553 Cancer Res 2006; 66: (7). April 1, 2006
cell lines in the absence of CD40 stimulation (Fig. 4B). This is
consistent with previous results that have identified constitutively
active LCK in the majority of B-cell malignancies (27). In
contrast, only CD40-sensitive OCI-Ly7 and Su-DHL4 cells (but not
CD40-resistant OCI-Ly1 or OCI-Ly8 cells) contained constitutively
phosphorylated ERK p42/p44 (Fig. 4B). As p38 and JNK are
activated by CD40 (28) and are downstream targets of VAV
(29, 30), we investigated the phosphorylation state of these
MAPK family proteins. p38 was constitutively phosphorylated in
all cell lines, and JNK was present but not phosphorylated in any
of the cell lines (data not shown).
LCK transgenic mice have been shown to develop thymic
lymphomas containing constitutively activated VAV and ERK, and
cell lines derived from such tumors were dependent on tyrosine
phosphorylation and Raf-dependent ERK activation for survival
(31). CD40-sensitive cell lines but not CD40-resistant cell lines
Figure 4. Functional analysis of differentially expressed CD40 signaling proteins. A, two genes involved in CD40-mediated ERK signaling are differentially expressed
among CD40-sensitive and CD40-resistant cell lines. Differences in expression levels based on oligonucleotide array analysis. Fold difference in expression could
not be calculated for VAV , as this mRNA was not detectable in CD40-resistant cells. Sites of action of two kinase inhibitors. B, activity of LCK and ERK was analyzed
with phosphorylation-specific antibodies. LCK was immunoprecipitated from nondenatured cell lysates and detected by Western blotting with phosphorylated Src
family antibody (phospho-SRC ). The blot was stripped and reprobed with an antibody against LCK. A commercially available Jurkat cell lysate was used as a
positive control. This sample was used without prior immunoprecipitation, allowing distinction of LCK from the slightly lower mobility band representing the antibody
used in immunoprecipitation. ERK was detected by immunoblotting with an antibody recognizing phosphorylated ERK1/2 (phospho ), and the blot was reprobed
with a pan-specific anti-ERK1/2 antibody (total ). C, sensitivity of the cell lines to inhibition of LCK and ERK activity was tested by addition of the Src family kinase
inhibitor PP1 or the MEK1/2 inhibitor U0126. Cells were incubated for 96 hours in inhibitor concentrations ranging from 104 to 108 mol/L, and viability was assessed
by MTT assay. Viability is expressed as a percentage of the absorbance compared with untreated samples. Results of two experiments with quadruplicate
samples each were combined. Bars, SD.
Figure 3. RT-PCR analysis of expression
levels of genes in the CD40 signaling
pathway. Expression of several genes, which
have shown differential expression by
oligonucleotide array analysis, was verified
by RT-PCR. PCR products were analyzed
by gel electrophoresis and photographed
with a Syngene gel documentation
system. A, representative gels from three
experiments. B, relative levels of expression
were quantitated with GeneTools software
by comparison with a standard curve
generated by amplification of PCR product
from serially diluted cDNA. Results from
triplicate samples. Bars, SD; where these
are not visible, variations between samples
were very small. N.D., not detected.
Cancer Research
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express VAV, a central part of the LCK-ERK signal transduction
pathway; therefore, we would expect growth of CD40-sensitive cells
but not CD40-resistant cells to be inhibited by blocking LCK or
ERK activity. Cells were exposed to a range of concentrations of the
Src family kinase inhibitor PP1 (32). As predicted by our model,
growth of CD40-sensitive OCI-Ly7 and Su-DHL4 cells was inhibited
more efficiently than growth of CD40-resistant OCI-Ly1 and
OCI-Ly8 cells (Fig. 4C). In contrast, similar experiments with the
MEK1/2 inhibitor U0126, which prevents phosphorylation of ERK
(33), did not show differential effects on growth of CD40-sensitive
and CD40-resistant DLBCL lines (Fig. 4C). These observations
suggest that LCK but not ERK is involved in maintaining growth of
CD40-sensitive DLBCL cell lines.
Phosphorylated ERK is required for CD40-mediated cell
death. CD40 stimulation has been shown to activate both ERK and
p38; however, inhibition of ERK but not p38 phosphorylation has
been reported to enhance CD40-mediated apoptosis in a
carcinoma cell line (34). We therefore determined the effect of
CD40 stimulation on ERK activation by Western blotting for
phosphorylated and total ERK. ERK was constitutively phosphor-
ylated in OCI-Ly7 and Su-DHL4 cells and not phosphorylated
before or after CD40 ligation in OCI-Ly1 and OCI-Ly8 cells (Fig. 5A).
This suggests that, unlike carcinoma cell lines, DLBCL cell lines do
not up-regulate ERK activity on CD40 signaling; however,
constitutively active ERK may influence the outcome of CD40
signaling. For example, if ERK protects DLBCL against CD40-
mediated apoptosis, inhibition of ERK before CD40 stimulation
should enhance cell death in OCI-Ly7 and Su-DHL4 cells by
reducing constitutive ERK activity, whereas OCI-Ly1 and OCI-Ly8
cells that lack active ERK should be unaffected by an ERK inhibitor.
This hypothesis was tested using pharmacologic inhibitors of MEK.
Phosphorylation of ERK was reduced after addition of the MEK
inhibitor U0126 (Fig. 5B). To determine if ERK is involved in CD40-
mediated cell death, cells were treated with the MEK1/2 inhibitors
U0126 or PD98058 before CD40 stimulation. The p38 inhibitor
SB230580, which has been shown previously to have no effect on
activation-induced cell death (11), was used as a negative control.
Viable cell counts were measured 96 hours after CD40 ligation. The
MEK1/2 inhibitors U0126 and PD98058 but not the p38 inhibitor
SB230580 reduced CD40-mediated cell death in OCI-Ly7 and Su-
DHL4 cells (Fig. 5C), suggesting that ERK promotes rather than
opposes activation-induced cell death in DLBCL cell lines.
Discussion
Differences in the effects elicited by CD40 stimulation in B-cell
lines suggest that different signal transduction pathways may be
expressed in CD40-sensitive and CD40-resistant cells. To assess
this, we did expression microarray studies on CD40-sensitive and
CD40-resistant DLBCL cell lines. Our observation that CD40-
sensitive and CD40-resistant cells display different gene expression
profiles suggests that these lines may be derived from two distinct
B-cell populations. CD40-sensitive cells overexpressed CD22 and
CD38, which are found on mature, activated B cells (35). CD40-
resistant cells expressed high levels of CD9, the recombination
activating genes RAG1 and RAG2 , and the pre-B-cell receptor genes
IGLL1 and VPREB1 , which are characteristics of pre-B cells at the
stage of immunoglobulin rearrangement (36–39) and have also
been detected in B lymphocytes in germinal centers (40). This
suggests that the CD40-sensitive OCI-Ly7 and Su-DHL4 cell lines
may be derived from mature, activated B cells, whereas the CD40-
resistant OCI-Ly1 and OCI-Ly8 cell lines resemble immature B cells.
We investigated expression of members of the CD40 signaling
pathway to determine the underlying mechanism of CD40-
mediated cell death. Failure of OCI-Ly1 and OCI-Ly8 cells to
undergo apoptosis on CD40 stimulation may be the result of
defects in the CD40 signal transduction pathway. These two cell
lines showed reduced expression of several genes involved in CD40
signaling, including LCK, VAV, and MEK1. Analysis of LCK by
RT-PCR and Western blot revealed that although RNA levels
differed among CD40-sensitive and CD40-resistant lines, all four
Figure 5. Constitutive ERK phosphorylation correlates with CD40-mediated cell
death. A, assessment of the phosphorylation state of ERK. Cytoplasmic cell
extracts were prepared from cells stimulated with cross-linked anti-CD40
antibody for 0 to 180 minutes. Total and phosphorylated ERK was detected
by Western blot. Blots were first probed with the phosphospecific antibody,
and the same membrane was reprobed for total protein with the pan-specific
antibody. B, reduction of ERK phosphorylation by U0126. Su-DHL4 cells were
incubated in the presence of 10 Amol/L U0126 for 48 hours, permeabilized
and stained with an anti-phosphorylated ERK antibody as described in Materials
and Methods, and analyzed by flow cytometry. C, effects of ERK inhibition
on CD40-mediated apoptosis. Cells were subjected to CD40 stimulation for
96 hours in the presence of the MEK1/2 inhibitors U0126 (10 Amol/L) or
PD98059 (50 Amol/L) or the p38 inhibitor SB203580 (10 Amol/L). Cell viability
was quantitated by staining nonpermeabilized cells with propidium iodide and
counting the number of unstained (live) cells per unit volume using a Becton
Dickinson FACScan flow cytometer set to count for 30 seconds. The number of
viable cells in anti-CD40-treated samples was expressed as a percentage of
the number of viable cells incubated in secondary antibody only. Results from
three experiments of four replicates each. Bars, SD. In the presence of
DMSO (control) or the p38 inhibitor SB203580, the number of viable OCI-Ly7
and Su-DHL4 cells was reduced by CD40 ligation (P < 0.01). The MEK1/2
inhibitors U0126 and PD98059 prevented CD40-mediated reduction in viability.
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cell lines expressed significant amounts of active LCK. This
suggests that differences in LCK mRNA levels may not have any
functional consequences. However, differences in VAV, a phos-
phorylation target of LCK, were striking, with strong mRNA
expression in CD40-sensitive lines and undetectable levels in CD40-
resistant lines. LCK and VAV have been shown previously to
maintain constitutive activation of ERK via stimulation of the Ras
pathway (31), which is consistent with our observation that ERK
was constitutively phosphorylated in CD40-sensitive DLBCL cell
lines but permanently inactive in VAV-deficient CD40-resistant
lines. Although all four cell lines expressed active LCK, the Src
family inhibitor PP1 was more effective at reducing proliferation of
OCI-Ly7 and Su-DHL4 cells. Differential sensitivity to PP1 could
result from inhibition of other Src family kinases or from the
differential function of downstream effectors, such as VAV, Ras, and
ERK. Lack of VAV and inactive ERK in OCI-Ly1 and OCI-Ly8 cells is
consistent with a dead end in the Src signal transduction pathway.
This could render the cells resistant to Src family kinase inhibitors
even if the targeted kinase itself is active.
ERK activation has often been reported to be antiapoptotic in
both lymphoid and nonlymphoid malignancies (34, 41); however,
the effect of ERK phosphorylation varies even among different
stimuli in the same cell line (12). We found that two different ERK
inhibitors did not affect the growth of DLBCL cell lines containing
activated ERK, which suggests that these lines are not dependent
on ERK signaling for survival or proliferation. Addition of ERK
inhibitors before CD40 stimulation blocked activation-induced cell
death, which indicates that overexpression or aberrant activation
of a protein in the ERK signaling cascade may sensitize DLBCL cell
lines to CD40. Our observation that ERK is constitutively active in
these cell lines suggests that the actual death signal must be
initiated by a second pathway when CD40 signaling occurs. ERK
has been implicated in apoptosis in other systems of activation-
induced cell death both directly and as a predisposing factor. T-cell
receptor (TCR)–mediated activation-induced cell death in a TCR
hybridoma cell line was shown to be mediated by activation of VAV
and ERK (42). Transfection of Rat-1 fibroblasts or MCF7 human
breast cancer cells with the ERK-regulated transcription factor Elk-
1 did not induce apoptosis directly but rendered the cells
susceptible to killing by a calcium ionophore (38). ERK may
function in a similar way in DLBCL cell lines, rendering cells
susceptible to a second signal caused by CD40 stimulation.
However, the signal is unlikely to be calcium mediated, as
treatment of the cells with the calcium ionophore ionomycin
induced cell death in Su-DHL4 cells but not OCI-Ly7 cells.3
Our observations on two pairs of cell lines are insufficient to
determine whether differential expression of maturation-specific
genes outside of the LCK-ERK pathway plays a role in determining
susceptibility to CD40-mediated cell death; however, they are
consistent with a previous report that B cells at different stages of
development differ in the protein phosphorylation patterns elicited
by CD40 stimulation (43). As CD40 signaling can promote
proliferation and resistance to apoptosis in normal B cells (44), it
is possible that constitutive activation of this pathway in a tumor
may lead to a more aggressive phenotype. DLBCL has been shown
to segregate into two subtypes with distinct gene expression
patterns, one resembling germinal center cells (germinal center
type) and the other similar to mature B cells that have been
subjected to CD40 and B-cell receptor stimulation (activated B-cell
type; ref. 45). The prognosis was shown to differ significantly, with
5-year survival being 76% for germinal center and 34% for
activated-type DLBCL (46). Neither the prevalence of constitutive
ERK activation in either subtype of DLBCL nor the correlation with
CD40 sensitivity has yet been investigated in tumor tissue. This
area may be fruitful for future investigation based not only on our
observations but also on recent development of inhibitors that
modulate relevant signal transduction pathways. The Src-VAV-ERK
signal transduction pathway is activated by both CD40 and B-cell
receptor signaling (12) and has been implicated in proliferation of
B-cell malignancies (41). Several proteins in this pathway, including
CD40, Src family kinases, Ras, and MEK, are being investigated as
targets for antitumor therapies (47–50).
Our studies show that increased expression of genes involved
CD40/BCR signal transduction coincided with constitutive ERK
activation and susceptibility to CD40-mediated cell death in
DLBCL cell lines. A constitutively active phenotype has been
previously associated with reduced survival in DLBCL (45). This
raises the question whether the poor prognosis of activated type
DLBCL may be the result of one or more overactive proteins in the
CD40 signal transduction pathway. An interesting but as yet
untested hypothesis is that the mechanism underlying the
aggressive nature of activated DLBCL may also be its Achilles
heel, leaving it vulnerable to therapies targeting the CD40 signal
transduction pathway.
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